The 17 most recent market catalysts affecting $IQV, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 13, 2026
Corporate Catalyst
Bearish
Impact 55
Court Dismisses Privacy Claims Against IQVIA in Rose v. IQVIA Holdings Inc.
A U.S. District Court dismissed privacy claims against IQVIA Holdings Inc. in a case alleging the company collected and shared sensitive medical information. This is a short-term p…
Oct 28, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Adjusts Price Target on IQVIA Holdings to $346 From $329, Maintains Buy Rating
Truist Financial has updated its assessment of IQVIA Holdings, raising the price target to $346 from $329 and maintaining a 'Buy' rating. This action signals increased confidence f…
Oct 14, 2026
Corporate Catalyst
Bullish
Impact 55
Stifel Maintains Buy on IQVIA Holdings, Raises Price Target to $303
Stifel analyst Shlomo Rosenbaum has raised the price target for IQVIA Holdings (IQV) from $276 to $303 while maintaining a 'Buy' rating. This action signals increased confidence fr…
Oct 13, 2026
Corporate Catalyst
Bullish
Impact 65
IQVIA Expands Partnership Veeva Systems On Enterprise Standard Applications That Will Be Used Across IQVIA Clinical Development Studies
IQVIA and Veeva Systems announced an expansion of their partnership, with IQVIA selecting Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise-standard applications for …
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on IQVIA Holdings, Raises Price Target to $300
Mizuho analyst Ann Hynes maintained an 'Outperform' rating on IQVIA Holdings and raised the price target from $275 to $300. This upgrade signals increased confidence from a major f…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on IQVIA Holdings, Raises Price Target to $300
Barclays analyst Luke Sergott maintained an 'Overweight' rating on IQVIA Holdings (IQV) and raised the price target from $275 to $300. This action signals a positive outlook from a…
Sep 30, 2026
Corporate Catalyst
Neutral
Impact 65
UBS Reinstates Buy on IQVIA Holdings, Announces $345 Price Target
UBS analyst Kevin Caliendo reinstated a 'Buy' rating on IQVIA Holdings (IQV) and announced a $345 price target. This analyst action signals a positive view from a significant finan…
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on IQVIA Holdings, Raises Price Target to $319
RBC Capital's analyst Ryan Halsted maintained an 'Outperform' rating on IQVIA Holdings and significantly raised the price target from $247 to $319. This action signals increased co…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
IQVIA And Medera Announce Strategic Collaboration To Accelerate Cardiac Gene Therapy Development And Human-Based Drug Discovery Platforms
This strategic collaboration is a positive catalyst for both IQVIA and Medera, as it leverages their respective strengths to tackle complex cardiac gene therapy development. IQVIA …
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
JP Morgan Maintains Overweight on IQVIA Holdings, Raises Price Target to $285
JP Morgan analyst Casey Woodring has maintained an 'Overweight' rating on IQVIA Holdings (IQV) and raised the price target from $225 to $285. This is a significant upgrade in the p…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
Stifel Maintains Buy on IQVIA Holdings, Raises Price Target to $276
Stifel analyst Shlomo Rosenbaum maintained a 'Buy' rating on IQVIA Holdings and significantly raised the price target from $220 to $276. This action signals increased confidence in…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on IQVIA Holdings, Raises Price Target to $247
RBC Capital's analyst Ryan Halsted has maintained an 'Outperform' rating on IQVIA Holdings (IQV) and raised the price target from $221 to $247. This action signals increased confid…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
BMO Capital Maintains Outperform on IQVIA Holdings, Raises Price Target to $270
BMO Capital analyst Sean Dodge maintained an 'Outperform' rating on IQVIA Holdings and raised the price target from $210 to $270. This is a significant upward revision, indicating …
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
Baird Maintains Outperform on IQVIA Holdings, Raises Price Target to $287
Baird analyst Eric Coldwell maintained an 'Outperform' rating on IQVIA Holdings and raised the price target from $252 to $287. This action signals a strong vote of confidence from …
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 85
IQVIA Holdings shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance.
IQVIA's strong earnings report and optimistic future guidance are a significant positive catalyst for the company, reflecting healthy underlying demand in the pharmaceutical and he…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 75
IQVIA Hldgs Q2 Adj. EPS $3.15 Beats $3.03 Estimate, Sales $4.368B Beat $4.301B Estimate
IQVIA Holdings announced its Q2 earnings, reporting adjusted EPS of $3.15, significantly beating the $3.03 consensus estimate, and sales of $4.368 billion, surpassing the $4.301 bi…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on IQVIA Holdings, Raises Price Target to $230
Mizuho analyst Ann Hynes maintained an 'Outperform' rating on IQVIA Holdings and raised the price target from $215 to $230. This action signals continued confidence in IQVIA's perf…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.